» Articles » PMID: 18682516

Treatment and Follow-up of Clinically Nonfunctioning Pituitary Macroadenomas

Overview
Specialty Endocrinology
Date 2008 Aug 7
PMID 18682516
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Although the majority of pituitary macroadenomas are clinically nonfunctioning, treatments as well as follow-up strategy for this condition lack evidence from randomized studies.

Evidence Acquisition: We evaluated the evidence of treatment and follow-up strategies for clinically nonfunctioning adenomas. PubMed was searched for articles on nonfunctioning adenomas in November 2007, and references of selected articles were assessed for potentially relevant articles.

Evidence Synthesis: All evidence for treatment and follow-up for nonfunctioning adenomas is based on observational studies. The most effective treatment is transsphenoidal surgery, indicated in patients with visual field defects. A wait-and-see approach may be considered in nonfunctioning macroadenomas not reaching to the optic chiasm. Some of these tumors ( approximately 10%) will show spontaneous regression, whereas in approximately 50% there will be progression within 5 yr observation. Postoperative radiotherapy should not be applied to all patients after surgery but can be considered in patients with large postoperative remnants of the tumor. During follow-up careful assessment and replacement of pituitary insufficiencies should be performed. Magnetic resonance imaging is advised with intervals of 1-3 yr and evaluation of visual fields when appropriate. Recurrence rates are reported to be 6-46% after transsphenoidal surgery, whereas after postoperative radiotherapy, recurrence rates of 0-36% are reported. Long-term sequelae of nonfunctioning macroadenomas are hypopituitarism, persistent visual field defects, and decreased quality of life. Whether nonfunctioning macroadenomas are associated with an increased mortality is still a matter of debate.

Conclusion: Clinically nonfunctioning pituitary macroadenomas, although benign in nature, need individualized treatment and lifelong radiological and endocrinological follow-up.

Citing Articles

Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol.

Bhatnagar A, Marin M, Lischalk J, Koh M, Agazzi S, Suy S Front Oncol. 2025; 15:1519445.

PMID: 39968072 PMC: 11832394. DOI: 10.3389/fonc.2025.1519445.


The expression of and family genes in pituitary adenomas: clinical correlations and postsurgical outcomes.

Facundo A, Magalhaes M, Nascimento G, Azulay R, Santos R, Freitas L Front Endocrinol (Lausanne). 2024; 15:1481050.

PMID: 39449743 PMC: 11499145. DOI: 10.3389/fendo.2024.1481050.


Lanreotide versus placebo for tumour reduction in patients with a Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.

Boertien T, Drent M, Booij J, Majoie C, Stokkel M, Hoogmoed J Lancet Reg Health Eur. 2024; 42:100923.

PMID: 39070749 PMC: 11281922. DOI: 10.1016/j.lanepe.2024.100923.


Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis.

Bioletto F, Sibilla M, Gasco V, Ghigo E, Grottoli S J Endocrinol Invest. 2024; 47(9):2143-2155.

PMID: 38503992 PMC: 11369010. DOI: 10.1007/s40618-024-02356-9.


Acromegaly with initial negative oral glucose tolerance test: a case report.

Tsai W, Chien M, Dai S, Chan Y J Med Case Rep. 2023; 17(1):333.

PMID: 37543629 PMC: 10404368. DOI: 10.1186/s13256-023-04064-z.